增强肝纤维化评分与肝硬度测量改善反映肝细胞癌风险降低
研究纳入453例接受抗病毒治疗的慢性乙型肝炎患者,这些患者在2006-2013年间接受瞬时弹性成像检查且LSM-HCC评分≥11(中高风险),至少3年后重复瞬时弹性成像并检测ELF评分。平均随访56个月期间45例(9.9%)发生肝细胞癌。联合LSM-HCC与ELF评分的敏感度(86.7%)和阴性预测值(95.3%)高于任一评分单独使用。
要点
- LSM-HCC评分≥11的慢性乙型肝炎抗病毒治疗患者中,联合ELF评分可提高HCC预测敏感度(86.7%)和阴性预测值(95.3%)。
- LSM-HCC评分改善、不变、恶化的患者分别占71.4%、24.3%、4.3%;ELF评分改善、不变、恶化的患者分别占36.9%、57.8%、5.3%。
- Kaplan-Meier分析显示ELF评分有助于进一步区分LSM-HCC中危患者的HCC风险(P=0.026),但对高危患者无此作用(P=0.770)。
核心结论
- 联合LSM-HCC评分与ELF评分的两步算法可提高接受抗病毒治疗的慢性乙型肝炎患者HCC预测准确性。
研究设计与样本
- 研究纳入2006-2013年间接受瞬时弹性成像检查、LSM-HCC评分≥11(中高风险)的慢性乙型肝炎患者,至少3年后重复瞬时弹性成像,并通过调取瞬时弹性成像检查前4周内储存的血清样本检测ELF评分,主要终点为HCC累积发生率。
- 共纳入453例慢性乙型肝炎患者(平均年龄51.7±10.3岁;男性74.4%),平均随访56个月期间45例(9.9%)发生HCC。
主要发现
- LSM-HCC评分改善、不变、恶化的患者分别占71.4%、24.3%、4.3%;ELF评分改善、不变、恶化的患者分别占36.9%、57.8%、5.3%。
- 联合LSM-HCC与ELF评分的敏感度(86.7%)和阴性预测值(95.3%)高于任一评分单独使用。
- Kaplan-Meier分析显示ELF评分有助于进一步区分LSM-HCC中危患者的HCC风险(P=0.026),但对LSM-HCC高危患者无此作用(P=0.770)。
关键数值与推荐
- LSM-HCC评分中高风险定义为11分或以上。
- 联合LSM-HCC与ELF评分的敏感度为86.7%,阴性预测值为95.3%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Liver stiffness measurement hepatocellular carcinoma (LSM-HCC) score predicts HCC accurately in patients with chronic hepatitis B (CHB). AIM: To assess the ability of LSM-HCC combined with enhanced liver fibrosis (ELF) score to predict HCC in CHB patients who received anti-viral treatment. METHODS: CHB patients who had transient elastography examinations in 2006-2013 with intermediate and high risk of HCC by LSM-HCC score (ie 11 or above) were assessed by repeat transient elastography at least 3 years later. ELF score was assessed by retrieving the stored serum samples 4 weeks within transient elastography examination. The primary endpoint was the cumulative incidence of HCC. RESULTS: A total of 453 CHB patients (mean age 51.7 ± 10.3 years; male 74.4%) were recruited, 45 patients (9.9%) developed HCC during the mean follow-up of 56 months. Regarding LSM-HCC score, 71.4%, 24.3% and 4.3% of patients had LSM-HCC score improved, remained static and deteriorated respectively; whereas 36.9%, 57.8% and 5.3% of patients had ELF score improved, remained static and deteriorated respectively. The sensitivity (86.7%) and negative predictive value (NPV) (95.3%) of combined LSM-HCC and ELF score were higher than that of each score alone. Kaplan-Meier analysis showed that ELF score would help further differentiate the HCC risk in patients with intermediate risk by LSM-HCC score (P = 0.026), but not in patients with high risk by LSM-HCC score (P = 0.770). CONCLUSIONS: The two-step algorithm combining LSM-HCC score and ELF score could improve the accuracy of predicting HCC of CHB patients receiving anti-viral treatment.
引用
- Liang LY, Wong VW, Tse YK, et al. Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2019. PMID: 31025388. doi:10.1111/apt.15269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。